Domainex is a well-respected, integrated drug discovery research services partner working globally with life science organisations, including biotechnology and pharmaceutical companies, patient foundations and academic institutes, to discover new medicines. We offer a suite of cutting edge technologies and a wealth of expertise to bring value to your drug discovery projects. Our proven track record and efficient processes will accelerate your research projects towards drug development.
Our innovative, customised suites of biology and chemistry technologies, spanning target expression to pre-clinical development candidate discovery are co-located to maximise the efficiency of your drug discovery projects. We deploy the latest techniques and utilise our proprietary technology platforms to create defined solutions for your project.
We work closely and collaboratively with our clients to understand their aspirations, bringing our ideas, know-how and wealth of experience to bear. Our clients often view us as an extension of their own resources and we have had numerous client testimonials to endorse this. We appreciate that there are no guarantees in successful outcomes from drug discovery. For us winning your trust and confidence early on forms the basis of successful research partnerships and we will be open and transparent with you with the challenges we see with your research projects. We are familiar and indeed encourage working towards interim and final research milestones as projects progress to stay highly focused on achieving the key objectives.
Our highly experienced, multi-disciplinary team of dedicated research scientists has a breadth of knowledge and industry experience, access to a wide range of technologies and a proven track record of success at all stages of pre-clinical drug discovery.
Approaches & Techniques
- CDH (Target Gene Fragmentation)
- LeadBuilder – Virtual Screening
- FragmentBuilder - Fragment Based Drug Discovery and Design
- Innovative Polymer Lipid Particle (PoLiPa) Technology
- Structure Based Drug Design (SBDD)
- Ligand binding assays by Surface Plasmon Resonance (SPR) and/or Grating-Coupled Interferometry (GCI)
- MicroScale Thermophoresis (MST) Services
- Differential Scanning Fluorimetry (DSF) and nanoDSF Services